FDA Approves DILTIAZEM HYDROCHLORIDE — Macleods Pharmaceuticals Limited

Macleods Pharmaceuticals Limited announced the FDA’s approval of its generic Diltiazem Hydrochloride oral tablets on February 27, 2026, facilitating the company’s expansion into the U.S. cardiovascular market. The approval positions Macleods to leverage generic price competition and challenge established branded players in this dosage form.